Skip to content

BioNeMo vs Recursion

A side-by-side comparison of BioNeMo and Recursion, two Science tools, drawn from Ignaite's continuously-verified listings.

Compared from listings verified as of

BioNeMo

Science

NVIDIA's development platform for AI drug discovery.

View BioNeMo

Recursion

Science

AI-driven drug discovery on the Recursion OS platform.

View Recursion

At a glance

Feature comparison of BioNeMo and Recursion
AttributeBioNeMoRecursion
CategoryScienceScience
Pricing (differs)FREEMIUMPAID
License (differs)Open coreProprietary
Deployment (differs)HybridCloud
Platforms (differs)API, LinuxWeb
Model supportSelf-contained (on-device)Self-contained (on-device)
Vendor (differs)NVIDIARecursion Pharmaceuticals

The honest brief

BioNeMo

GPU-optimized recipes claim ~2x faster biofoundation-model training and ~6x faster inference versus unoptimized pipelines.

  • Open-source framework (Apache-2.0)
  • Prebuilt models for protein and molecule tasks
  • NIM microservices for production deployment
  • Bundles datasets and training recipes
  • Requires NVIDIA GPUs
  • Steep learning curve for non-ML scientists
  • Production microservices are paid

Recursion

Runs a vast in-house automated wet lab generating millions of cell experiments weekly, feeding a 50+ petabyte dataset few rivals can match.

  • Recursion OS with LOWE language layer
  • Massive proprietary biology dataset
  • Natural-language target and compound queries
  • Public company with pharma partners
  • No self-serve product or API
  • Partner and internal use only
  • Opaque pricing
  • No approved drug yet